Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
Yu Yoshida, Yoshimitsu Naoe, Taro Terauchi, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 11, pp. 4648-4664
Closed Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

The “Cyclopropyl Fragment” is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules
Tanaji T. Talele
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 19, pp. 8712-8756
Closed Access | Times Cited: 792
G protein-coupled receptors: structure- and function-based drug discovery
Dehua Yang, Qingtong Zhou, Viktorija Labroska, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 419
On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
Annemiek Vermeeren, Stefan Jongen, Patricia Murphy, et al.
SLEEP (2018) Vol. 42, Iss. 4
Open Access | Times Cited: 215
Fluorine-containing drugs approved by the FDA in 2019
Haibo Mei, Attila Márió Remete, Yupiao Zou, et al.
Chinese Chemical Letters (2020) Vol. 31, Iss. 9, pp. 2401-2413
Closed Access | Times Cited: 195
Novel 1,2,4-Oxadiazole Derivatives in Drug Discovery
Karol Biernacki, Mateusz Daśko, Olga Ciupak, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 6, pp. 111-111
Open Access | Times Cited: 139
An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
Christopher M. Marshall, John G. Federice, Chloe N. Bell, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11622-11655
Closed Access | Times Cited: 110
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation
Chuan Hong, Noel Byrne, Beata Zamlynny, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 104
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
Carla Rizzo, Sara Amata, Ivana Pibiri, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7728-7728
Open Access | Times Cited: 50
The Orexin/Hypocretin System, the Peptidergic Regulator of Vigilance, Orchestrates Adaptation to Stress
Miklós Jászberényi, Balázs Thurzó, Zsolt Bagosi, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 448-448
Open Access | Times Cited: 22
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 2, pp. 287-295
Open Access | Times Cited: 89
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Nickel‐Catalyzed Asymmetric Hydroaryloxy‐ and Hydroalkoxycarbonylation of Cyclopropenes
Rongrong Yu, Song‐Zhou Cai, Can Li, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 36
Closed Access | Times Cited: 52
Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
T. N. Rekha, Dongyun Shin
Pharmaceuticals (2023) Vol. 16, Iss. 3, pp. 339-339
Open Access | Times Cited: 22
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Direct Synthesis of Cyclopropanes from gem-Dialkyl Groups through Double C–H Activation
Antonin Clemenceau, Pierre Thesmar, Maxime Gicquel, et al.
Journal of the American Chemical Society (2020) Vol. 142, Iss. 36, pp. 15355-15361
Open Access | Times Cited: 65
Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis
Mathieu Rappas, A. Ali, K.A. Bennett, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 4, pp. 1528-1543
Open Access | Times Cited: 65
Lemborexant: First Approval
Lesley J. Scott
Drugs (2020) Vol. 80, Iss. 4, pp. 425-432
Closed Access | Times Cited: 62
Palladium-Catalyzed Annulations via Sequential C–H Activations of C(sp2)–H/C(sp3)–H or C(sp3)–H/C(sp3)–H Bonds
Wan‐Xu Wei, Mateusz Czajkowski, Yangjin Kuang, et al.
ACS Catalysis (2024) Vol. 14, Iss. 9, pp. 6535-6546
Open Access | Times Cited: 6
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan, Bin Yu, Hong‐Min Liu
European Journal of Medicinal Chemistry (2020) Vol. 205, pp. 112667-112667
Closed Access | Times Cited: 49
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single‐Dose and Multiple‐Ascending‐Dose Phase 1 Studies in Healthy Adults
Ishani Landry, Kenya Nakai, Jim Ferry, et al.
Clinical Pharmacology in Drug Development (2020) Vol. 10, Iss. 2, pp. 153-165
Open Access | Times Cited: 48
Synthetic Approaches to the New Drugs Approved during 2019
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3604-3657
Closed Access | Times Cited: 36
Page 1 - Next Page

Scroll to top